News

GSK enters US$200m PPP
Enlarge image

BusinessUK

GSK enters US$200m PPP

24.05.2013 - GSK has entered into a public-private partnership with the federal US agency BARDA to develop new antibiotics and drugs against potential bioweapons.

The first-ever public-private partnership of the Biomedical Advanced Research and Development Authority (BARDA) with a pharma company could be worth up to US$200m if the collaboration proves effective after 18 months. The two partners will jointly develop anti-infectives to treat infections with bugs that have become a medical threat due to their resistance to common antibiotics. Additionally, the collaboration aims at developing drugs against pathogens that could become a civil threat due to their potential use as a bioweapon. Both topics are priorities of the National Health Security Strategy as well as the BARDA’s 2011-2016 working plan.

The initial funding for the Public-Private Partnership of US$40m for the first 18 months will give GSK the possibility to further develop promising candidates from its antibiotics portfolio with a lowered investment risk for the drugmaker. While return-on-investment in the antibiotics space has become low, most large drug-makers have focused on more lucrative and financially less risky disease areas. David Payne, head of GSK's antibacterial discovery unit, said public-private partnerships, like the one with BARDA, were a key part to solving the problem.

GSK is already involved in the Innovative Medicine’s Initiative’s programme against antibiotic resistance. But while the IMI programme is focused on bringing Phase III drugs to the market and to find strategies against Gram-negative bacteria, the compounds covered by the BARDA deal are still in early safety testing.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/gsk-enters-us200m-ppp.html

FinancingFrance

21.10.2014 Yet another European company is looking for money on the US stock exchange – French DBV Technologies SA is all set up for its secondary listing on NASDAQ. The French biotech company hopes to rake in US$98m for its peanut allergy patches.

FinancingDenmark

18.10.2014 After raising US$220.5m (€172m) with its IPO, fast Forward Pharma’s lucky streak hits an obstacle on the road to success with shares falling 17% on its first day of trading.

M&AUKItaly

17.10.2014 Abandoned at the altar: Abbvie has dropped plans to acquire UK’s Shire following new US tax rules. This puts a stop to one of the biggest pharma mergers planned this year.

FinancingUKBelgium

15.10.2014 Bicycle Therapeutics wins €25m backing by major pharma venture capitalists for the development of a new class of oncology drugs.

FinancingGermanySwitzerlandNetherlands

13.10.2014 Biotechnology IPOs are back in fashion – German Probiodrug AG wants to raise €32m with its IPO, whilst Swiss Molecular Partners AG hopes the launch of its IPO will gain a revenue of €145m.

BusinessIreland

10.10.2014 Actavis has announced plans to merge with American pharma company Durata - a move that will strengthen their infectious diseases portfolio.

RegulationEU

07.10.2014 In an unprecedented move, the European Medicines Agency has approved a system allowing the future analysis of clinical trial data.

FinanceNetherlandsEU

06.10.2014 Another fund from the Netherlands has raised €92m in its first close and will invest the money in companies developing innovative therapeutics, medical devices and diagnostics.

FinanceNetherlandsUKSwitzerland

03.10.2014 Dutch venture capitalist LSP has achieved its monetary milestone by raising €80m for its fifth fund - with a goal of €150m.

PoliticsEULithuaniaPoland

02.10.2014 New EU commission chief Jean-Claude Juncker is on the defensive after members of Parliament and NGOs criticised his reorganisation of the health technology units.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MEDIGENE3.85 EUR8.15%
  • EVOTEC2.87 EUR7.49%
  • 4SC0.84 EUR5.00%

FLOP

  • CYTOS0.15 CHF-6.25%
  • EPIGENOMICS3.42 EUR-0.87%
  • STRATEC BIOMEDICAL37.50 EUR-0.87%

TOP

  • BIOFRONTERA2.91 EUR29.9%
  • ADDEX3.44 CHF5.8%
  • HBM86.00 CHF3.7%

FLOP

  • PAION2.19 EUR-32.6%
  • CYTOS0.15 CHF-28.6%
  • 4SC0.84 EUR-26.3%

TOP

  • SANTHERA82.00 CHF2269.9%
  • CO.DON2.82 EUR209.9%
  • PAION2.19 EUR154.7%

FLOP

  • CYTOS0.15 CHF-96.2%
  • 4SC0.84 EUR-51.7%
  • THERAMETRICS0.07 CHF-46.2%

No liability assumed, Date: 21.10.2014